Skip to search formSkip to main contentSkip to account menu

Aurora A Kinase Inhibitor TAS-119

Known as: TAS-119, TAS-2104 
An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon… 
National Institutes of Health

Related topics

Related topics

2 relations
Aurora Kinase ANCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.
3063 Background: AurA is a serine threonine kinase regulating cell division and cell cycle progression and has a role in… 
2014
2014
398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer models
2014
2014
433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase
2014
2014
434 Bipolar androgen therapy for men with castration sensitive and castration resistant prostate cancer: Reversing resistance and maintaining sensitivity to androgen ablative therapies
2014
2014
399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study
2012
2012
252 TAS-2104, a Highly Potent and Selective Aurora A Inhibitor, Enhanced Antitumor Activity of Taxanes in Vivo
2012
2012
251 Highly Potent and Selective Aurora A Inhibitor, TAS-2104 Enhanced Antitumor Activity of Taxanes in Vitro
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)